Plain-English translation of NCT07240012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a newer way to deliver insulin called CamAPS FX — an automated system that helps manage blood sugar automatically — in women with type 1 diabetes who are planning pregnancy or already pregnant. The study compares this automated system to standard insulin treatment (injections or pumps) to see which approach helps keep blood sugar better controlled and supports healthier fetal growth during pregnancy.
Pregnancy is a time when blood sugar control becomes extra important for both mother and baby, but it can be challenging to manage with standard insulin treatment alone. This trial is testing whether the automated system can make blood sugar management easier and safer during this critical time.
You likely qualify if…
You likely don't qualify if…
If you're planning pregnancy, you'll either receive the CamAPS FX automated insulin system or continue your current insulin treatment for up to 52 weeks (or until you become pregnant, whichever comes first). If you're already pregnant at enrollment, you'll follow the same assignment throughout your pregnancy and for one month after delivery. You'll have regular check-ins with your diabetes care team and local pregnancy specialists to monitor your blood sugar control and your baby's growth.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Denmark